Spontaneous Tumor Lysis Syndrome as a Complication of Metastatic Breast Cancer: A Rare Case Report
DOI:
https://doi.org/10.61186/Keywords:
Spontaneous tumor lysis syndrome, Breast cancer, Acute kidney injuryAbstract
Tumor lysis syndrome (TLS) is a well-established potentially fatal condition which is considered an oncologic emergency. TLS typically develops from the rapid lysis of neoplastic cells after the commencement of cytotoxic treatment in patients with some kinds of lymphomas, especially the Burkitt variant, and acute lymphoblastic leukemia. Spontaneous TLS (STLS), a variant of TLS occurring in the absence of chemotherapy or radiation therapy, has been observed in non-Hodgkin lymphoma and acute leukemia, and rarely in solid neoplasms. In this paper, we present a 62-year-old woman with STLS, secondary to metastatic breast cancer. Unfortunately, she died because of complications of acute kidney injury, especially severe metabolic acidosis that was refractory to hemodialysis. Although it is infrequent, healthcare professionals should consider STLS as a probable consequence of breast cancer characterized by a high tumor burden and distant metastases.
Downloads
References
1. Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med 2011;364:1844-54. doi:10.1056/NEJMra0904569.
2. Papapanou M, Athanasopoulos AE, Georgiadi E, et al. Spontaneous tumor lysis syndrome in patients with solid tumors: a scoping review of the literature. Med Oncol. 2023;40:233. doi: 10.1007/s12032-023-02108-4.
3. Coiffier B, Altman A, Pui C-H, Younes A, et al. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol. 2008; 26:2767-2778. doi: 10.1200/JCO.2007.15.0177.
4. Mirrakhimov AE, Ali AM, Khan M, et al. Tumor lysis syndrome in solid tumors: an up to date review of the literature. Rare Tumors. 2014;6:68-76. doi: 10.4081/
rt.2014.5389.
5. Alqurashi RM, Tamim HH, Alsubhi ZD, Alzahrani AA, Tashkandi E. Tumor lysis syndrome in patients with solid tumors: a systematic review of reported cases. Cureus. 2022;14. e30652. doi: 10.7759/cureus.30652. eCollection 2022 Oct.
6. Gemici C. Tumour lysis syndrome in solid tumours. Clin Oncol (R Coll Radiol)2006;18:773-80. doi: 10.1016/j. clon.2006.09.005.
7. Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol. 2004;127:3-11. doi: 10.1111/j.1365-2141.2004.05094.x
8. Sommerhalder D, Takalkar AM, Shackelford R, Peddi P. Spontaneous tumor lysis syndrome in colon cancer: a case report and literature review. Clin Case Rep.2017;5:2121-2126. doi: 10.1002/ccr3.1269.
9. Crittenden DR, Ackerman GL. Hyperuricemic acute renal failure in disseminated carcinoma. Arch Intern Med. 1977;137:97-99.
10. Robbin BT, Kreimer AM, Patel RA, Butts AR. Spontaneous Tumor Lysis Syndrome in a Patient with Stage IV HER2-Positive Breast Cancer: Case Report. J Hematology Oncology Pharmacy. 2022; 12: 19-23.
11. Cordrey EO, Dienhart JA, Wang J. Spontaneous tumor lysis syndrome in a giant neglected breast cancer. J Mol Oncol Res. 2018;2:38-41.
12. Elfar A, Teleb M, Rodriguez-Castro CE, Nahleh Z. Spontaneous tumor lysis syndrome in breast cancer:
a case report and discussion. journal of Cancer Therapeutics and Research. 2013;2:9.
13. Goyal H, Sawhney H, Singh J. Spontaneous fatal recurrent tumor lysis syndrome in ductal breast carcinoma. Community Oncology. 2012; 9:136-137.
14. Mott FE, Esana A, Chakmakjian C, Herrington JD. Tumor lysis syndrome in solid tumors. Support Cancer Ther. Apr 1 2005;2:188-91. doi:10.3816/SCT.2005.n.012
15. Parsi M, Rai M, Clay C. You can’t always blame the chemo: a rare case of spontaneous tumor lysis syndrome in a patient with invasive ductal cell carcinoma of the breast. Cureus. 2019;11:e6186. doi: 10.7759/cureus.6186.
16. Sklarin NT, Markham M. Spontaneous recurrent tumor lysis syndrome in breast cancer. Am J Clin Oncol
1995;18:71-73. doi: 10.1097/00000421-199502000-00015.
17. Kjellstrand CM, Cambell DC 2nd, von Hartitzsch B, Buselmeier TJ. Hyperuricemic acute renal failure. Arch Intern Med. 1974; 133:349-59.
